AstraZeneca, the global pharmaceutical giant, has been making major moves in the market, leading to fluctuating stock performance. Despite a brief decline, the overall market continues its improvement, raising investor interest. Recent developments include an upgrade to a
Buy rating at Jefferies due to a
undervalued oncology portfolio and significant boosts to stock holdings by Hantz Financial Services and Jennison Associates. However, Deutsche Bank downgraded AstraZeneca to Sell due to concerns over its pipeline. A negotiated drug pricing deal with the White House, along with plans to list shares directly on the New York Stock Exchange, have contributed to a rise in stock prices. This has coincided with a surge in share price, sparking fresh debates about the company's valuation. AstraZeneca also finalised another drug-pricing agreement, mitigating tariff threats and price control concerns. However, following the cut in UK investment, the company's shares fell 3%. Despite these setbacks, analysts remain confident in the company's long-term momentum, with Goldman Sachs raising its stock target based on the potential of a $3.7 billion drug.
AstraZeneca Stocks News Analytics from Tue, 01 Jul 2025 07:00:00 GMT to Sat, 01 Nov 2025 09:11:01 GMT -
Rating 3
- Innovation -7
- Information 6
- Rumor -6
